$CAPR After $REPL: Does Tudriqev’s FDA Approval Create a Real Path for Deramiocel?

The immediate trigger for this article is the discussion now running through the $CAPR Stocktwits stream. The community is not arguing about one thing; it is arguing about four different things at once: whether REPL creates a regulatory precedent, whether HOPE-3’s statistical-analysis-plan changes amount to “p-hacking,” whether a Lancet publication should carry more regulatory weight, and whether Capricor needs a reset in how it engages with FDA.

Those are all legitimate questions. But social media is useful here as a question generator, not as an evidence source. The evidence has to come from the FDA briefing packages, the sponsor’s response, the advisory votes, the approval outcome and the underlying clinical literature.

1. What REPL actually proved — and what it did not

Replimune’s path was hardly a clean approval story. FDA had already issued two CRLs for RP1, now marketed as Tudriqev (vusolimogene oderparepvec), in combination with nivolumab for advanced melanoma after prior anti-PD-1 therapy. In its July 30 briefing package, the FDA review team remained highly critical: the pivotal IGNYTE dataset was single-arm, the agency questioned response-assessment methodology, contribution of effect from RP1 versus nivolumab, the reliability of historical controls and whether the observed response signal was strong enough to support accelerated approval.

Yet the FDA document also contained the line that matters most for the CAPR debate: because of the unmet need in this melanoma population, the agency said it had exercised regulatory flexibility by agreeing to review a single-arm dataset. That did not mean the staff review was positive; it meant FDA was willing to consider a less conventional evidentiary package in a serious disease setting. Read the FDA REPL briefing document.

The outside committee then voted 10–3 in favor of the RP1 package, and on August 6 FDA approved Tudriqev under the accelerated-approval pathway. A Phase 3 confirmatory study is ongoing, with results expected in 2030. The reported approval dataset showed an objective response rate of 24.2% and a median response duration of 14.1 months. Reuters coverage of the approval.

But that is very different from saying FDA can simply “give CAPR the REPL deal.” Accelerated approval is not a sympathy mechanism. FDA’s own program requires an adequate evidentiary basis around a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit, with confirmatory work required to verify that benefit. FDA Accelerated Approval Program.

2. CAPR and REPL are regulatory cousins — not scientific twins

That last row is the most important. REPL’s weakness was obvious: the absence of a randomized control arm in the registration dataset. CAPR’s problem is more awkward. HOPE-3 actually has the trial architecture regulators normally prefer — randomized, blinded and placebo-controlled — but FDA argues that the interpretation changed enough after study completion to undermine confidence in what that randomized trial really proved.

So the CAPR bull case cannot simply say, “Our trial is better designed than REPL’s.” It has to answer the harder question: why should FDA accept the sponsor’s final HOPE-3 analysis as the correct, prospectively legitimate analysis of that trial?

3. The SAP dispute is not a side issue. It is the CAPR case.

Capricor says its results are governed by SAP version 3.0, finalized before unblinding, and that FDA’s reliance on SAP 1.1 is inappropriate because that earlier document was an unsigned, incomplete internal draft that became obsolete after Cohort B was added and did not contain later FDA-requested content. Capricor’s July 27 response.

FDA sees the chronology differently. Its briefing document says the randomized double-blind portion of HOPE-3 was completed in June 2025, while later SAP versions changed endpoint definitions, models and missing-data strategies. FDA also says SAP 3.0 was not submitted for agency review before the BLA submission and that the final clinical-study-report analyses included further modifications. On that basis, FDA treats the later analyses as post-study and questions their reliability. FDA deramiocel briefing document.

The resulting p-value evolution is extraordinary — and this is why the argument has become so heated.

4. Is this “p-hacking”? That accusation is too simple.

One of the sharper comments circulating in the community is that the changing p-values prove p-hacking. That is an understandable reaction to a chart where a primary endpoint moves from p=0.24 under one analysis to p=0.029 in the applicant’s final CSR analysis, while LVEF moves from p=0.97 to p=0.041.

But “p-hacking” is a loaded conclusion, not a neutral description of what FDA has established. FDA’s documented argument is more specific: post-study changes to endpoint definitions, covariates, missing-data handling and other analytical choices can increase bias and Type I error risk, and the fact that a small number of observations can move the conclusion across the 0.05 threshold makes the result less robust.

For PUL, the applicant’s CSR analysis reported a 4.55-percentage-point between-group difference with p=0.029. FDA then applied the SAP 3.0 model with the earlier missing-data/intercurrent-event handling and obtained a 2.53% difference with p=0.21. For LVEF, the applicant’s ranked analysis reported p=0.041; FDA’s alternative handling produced p=0.22. Those are not cosmetic differences. They are the heart of FDA’s robustness objection.

This is why the next constructive CAPR debate should be less about insults and more about chronology: When was each decision made? Who had access to what data? Which changes were necessitated by Cohort B or FDA requests? Which were statistical refinements? Which materially changed the treatment estimate? That is the argument FDA ultimately has to resolve.

5. “But CAPR has The Lancet.” Yes — and this is stronger than a historical HOPE-2 argument.

This point needs to be stated precisely. On July 29, 2026, The Lancet published the pivotal Phase 3 HOPE-3 trial itself: “Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial.” The 106-patient study reported a statistically significant benefit on the sponsor’s primary PUL 2.0 analysis and cardiac findings under the analysis framework used in the publication. Open the HOPE-3 paper via DOI. Capricor states that the published results are based on SAP 3.0. Capricor’s July 29 publication announcement.

That materially strengthens the scientific side of the bull argument. Independent peer review means the pivotal dataset, methodology and interpretation were considered publishable in a top medical journal; this is not merely an old Phase 2 paper being used to defend a later trial. HOPE-2 was also published in The Lancet in 2022, so Capricor can point to peer-reviewed randomized evidence across both Phase 2 and Phase 3 development.

But peer review and FDA approval answer different questions. A journal can conclude that an analysis framework is scientifically coherent and worthy of publication while FDA can still ask whether that framework was locked early enough, followed the trial’s blinding plan, handled intercurrent events appropriately and is robust enough to satisfy the statutory standard for substantial evidence. FDA’s July 2026 briefing specifically argues that SAP 3.0 was finalized after the double-blind study period ended, one day before database lock/unblinding, was not submitted to FDA for prior review, and was followed by additional CSR modifications.

6. The most provocative community question: why not approve CAPR with a confirmatory trial?

This is where the REPL comparison becomes genuinely useful.

Tudriqev was approved through accelerated approval while a confirmatory Phase 3 trial continues. So why could FDA not do something conceptually similar for deramiocel?

The answer is that a confirmatory requirement does not solve the first problem automatically. FDA still needs a legally supportable basis for approval today. In accelerated approval, that generally means an effect on a surrogate endpoint or intermediate clinical endpoint considered reasonably likely to predict clinical benefit. The confirmatory trial verifies the anticipated benefit later; it does not replace the initial evidence threshold.

For REPL, oncology has a long regulatory history of using response-based endpoints in accelerated approval, particularly objective response rate plus durability when the effect is sufficiently persuasive. FDA still fought with Replimune over whether IGNYTE’s response data met that standard — but the framework itself was familiar.

For CAPR, the obvious candidate endpoints raise different problems:

That produces the single best question for the CAPR community:

That is much more useful than saying “REPL got one, so CAPR should get one.”

7. Does Capricor need a regulatory reset?

Another theme in the current discussion is more personal: some shareholders want different people representing Capricor in future FDA interactions. That is emotionally understandable after a 3–9 vote and a public clash over statistical plans, but the useful governance question is not whether one executive should be “blamed.”

The useful question is whether the next regulatory interaction — if FDA does not approve the current BLA — can produce a prospectively locked framework that removes the ambiguity now poisoning the debate.

Ideally, any future pivotal or confirmatory plan would leave as little interpretive space as possible around:

• the exact target population and cardiomyopathy definition;
• the primary endpoint and its clinically meaningful effect size;
• the statistical model and covariates;
• missing-data and intercurrent-event rules;
• cardiac imaging acquisition and reader methodology;
• the confirmatory role, if any, of PUL, LVEF, LGE and other measures;
• what must be agreed with FDA before database lock and unblinding.

That would be a regulatory reset in the constructive sense: not a change of personalities for its own sake, but a process in which the sponsor and agency reduce the probability that they arrive at the end of another expensive trial arguing over which statistical plan counts.

8. What REPL changes in the CAPR bull case — and what it does not

9. The timeline that now matters

For the full pre-PDUFA history and the broader commercial/legal setup, see the CAPR Stock Hub. For the earlier back-to-back setup before both advisory meetings, see FDA Showdown Week: Capricor and Replimune. Replimune’s deeper platform background is available in the REPL deep dive.

10. Merlintrader read-through: REPL improves CAPR optionality, not CAPR probability by itself

The strongest conclusion is deliberately uncomfortable for both sides.

Bears are wrong if they treat the 3–9 vote as proof that approval is procedurally impossible. FDA advisory votes are non-binding, and REPL has just provided a dramatic reminder that regulatory outcomes can change when outside experts, unmet need and a workable post-approval framework alter the total record.

Bulls are wrong if they treat Tudriqev as a direct precedent that should force FDA to approve deramiocel. REPL’s approval does not resolve whether HOPE-3’s later analyses are sufficiently pre-specified, robust and clinically interpretable. It also does not identify the endpoint FDA would use if it wanted to construct an accelerated-approval or other postmarketing-confirmation path for CAPR.

What REPL does is restore optionality to the discussion. It proves that FDA can be flexible after a damaged review. It does not tell us that FDA will find a legal and scientific route through CAPR’s specific statistical dispute.

Between now and August 22, the smartest question is therefore not “Will FDA copy REPL?” It is:

If the answer is yes, REPL shows that a surprising outcome is possible. If the answer is no, unmet need and patient testimony cannot substitute for the statutory evidence standard.